Mouse Genome Informatics
cn
    Tg(CAG-lacZ,-SV40)#Bcv/0
involves: FVB/N
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       
mortality/aging
• recombinant adenoviruses Ad5CMVeGFP (AdGFP) or Ad5CMVCre (AdCre) are delivered to the ovarian surface epithelium (OSE) in vivo via intrabursal injection
• with a median survival of 113 days after injection
• decreased survival time in mice treated with exogenous 17beta-estradiol (E2) (50 vs. 113 days after AdCre)

tumorigenesis
• develop more tumors in the urogenital tissues (uterus, cervix, bladder, and urethra) after E2 treatment
• tumors from P4 treatment have a more diffuse pattern and a higher incidence of zellballen
• tumors from E2-treated mice display a more diffuse appearance, abundant surface papillae, and large areas of necrosis
• E2 treatment accelerates tumor onset
• develop more tumors in the urogenital tissues (uterus, cervix, bladder, and urethra) after E2 treatment
• mice (9 of 11) develop large, well-vascularized ovarian tumors after intrabursal administration of adenovirus expressing Cre recombinase (J:158388)
• tumors have characteristics reflective of sex cord stromal tumors, including cysts and areas of cords or insular formations (J:158388)
• nascent tumors from the OSE layer, invading into the ovary 80-90 days after introduction of Cre recombinase (n=8) (J:158388)
• frequently (89%) accompanied by metastases to the diaphragm, liver, pancreas, spleen, intestines, body wall, uterus, and/or oviduct (J:158388)
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy
• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy
• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy
• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas
• decreased incidence of ovarian neoplasms (64 vs. 82% in controls) in progesterone (P4)-treated mice (n=11)

homeostasis/metabolism
• peritoneal ascites with volumes ranging from 0.5-7.5 ml in 64% of the mice
• accumulation of ascites and adhesions in the abdomen in one mouse without ovarian tumor (out of 11 mice)
• E2 treatment decrease the incidence of peritoneal ascites accumulation

muscle
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy

Mouse Models of Human Disease
OMIM IDRef(s)
Ovarian Cancer 167000 J:158388